Cargando...
Rosiglitazone disrupts endosteal bone formation during distraction osteogenesis by local adipocytic infiltration
Rosiglitazone (Rosi) is a drug in the thiazolidinedione class for treatment of Type 2 diabetes mellitus (T2DM), which binds and activates PPARγ nuclear receptor in fat cells, sensitizing them to insulin. Despite proven antidiabetic efficacy, Rosi therapy may be associated with trabecular bone loss a...
Gardado en:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2012
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3513662/ https://ncbi.nlm.nih.gov/pubmed/23069375 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bone.2012.09.038 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|